(Q42921533)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806321%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806321%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

1 reference

metastatic renal cell carcinoma

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806321%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

Jorge A Garcia

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806321%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Thomas E Hutson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806321%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Paul Elson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806321%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

C Lance Cowey

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806321%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Cheryl Nemec

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806321%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Robert Dreicer

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806321%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Ronald M Bukowski

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806321%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Brian I Rini

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806321%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

language of work or name

English

0 references

publication date

30 August 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806321%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806321%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

116

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806321%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806321%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

5383-5390

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806321%20AND%20SRC:MED&resulttype=core&format=json

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

13 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25327

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25327

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25327

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25327

Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25327

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25327

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25327

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25327

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25327

Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25327

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25327

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25327

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25327

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.25327

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20806321%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference